Inclusion Criteria:

- Histologically confirmed neoplasm of the upper gastrointestinal tract (pancreas,
stomach, duodenum, common bile duct, ampulla of Vater) or metastatic tumor to the
upper abdomen.

- Eligible patients include patients with locally advanced unresectable tumors,
positive surgical margins, local recurrence and resected stage II-III pancreatic,
gastric, duodenum, bile duct or ampulla of Vater carcinoma.

- Performance status SWOG 0-2

- Fully recovered from prior surgery or chemotherapy (greater than or equal to 4
weeks). Patients previously treated with 5-FU or gemcitabine may start therapy 2
weeks after the last dose of 5-FU or gemcitabine.

- Absolute granulocyte count (AGC) > 1500; platelets > 100,000; serum creatinine < 2.0
mg/dl; total bilirubin < 2.0 mg/dl; AST or ALT and alkaline phosphatase < 3 times the
upper limit of normal.

- Prior chemotherapy is allowed.

Exclusion Criteria:

- Prior radiation therapy to the upper abdomen

- Tumors of the gastroesophageal junction.

- Other medical, psychological or social circumstances that, in the opinion of the
investigator, would prevent participation in the clinical trial

- Pregnancy.